Activity of Seviteronel in Patients With Androgen Receptor (AR)-Positive Glioblastoma

NCT03600467 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

4

Enrollment

OTHER

Sponsor class

Stopped Sponsor

Conditions

Solid Tumor
Androgen Receptor Gene Overexpression

Interventions

DRUG: SEVI-D (Seviteronel in combination with dexamthasone)

Sponsor

St Vincent's Hospital, Sydney